HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Explains Food Allergen Evaluations, Offers Instructions On Making Requests For More

Executive Summary

Draft asks for comments on a guidance which will outline FDA thinking evaluating public health importance of food allergens not identified as major.. Draft also provides information on submitting requests to evaluate non-listed food allergens.

You may also be interested in...



US FDA Guidance Scratches Sesame Labeling Itch; House Passes ‘FASTER’ Allergen Identity Process

Food Allergy Safety, Treatment, Education, and Research Act would amend FDA regulations to include sesame as major allergen and allow agency to add other food ingredients as major allergens based on prevalence and severity of allergic reactions. FDA, meanwhile, published guidance for voluntarily labeling sesame as an allergen while it develop its factors for evaluating which food allergens in addition to the eight already specified in its regulations should be designated as requiring additional controls, including allergen labeling.

FDA Guidance Clarifies Labeling For Supplements Containing Food Allergens

Manufacturers of dietary supplements are required to begin labeling products that contain major food allergens on Jan. 1 in order to comply with the Food Allergen Labeling & Consumer Protection Act of 2004 (FALCPA)

Ultrahuman Expands Wearable Medtech Production Into US After $35M Funding Round

Firm operating in London, India and United Arab Emirates says its “Ultra Factory” will open in Indiana within the next six months with end-to-end production based on its operational facility in India.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152429

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel